Literature DB >> 9146007

Associations among cystoscopic and urodynamic findings for women enrolled in the Interstitial Cystitis Data Base (ICDB) Study.

D A Nigro1, A J Wein, M Foy, C L Parsons, M Williams, L M Nyberg, J R Landis, Y L Cook, L J Simon.   

Abstract

OBJECTIVES: Interstitial cystitis is a symptom complex characterized by pelvic pain, urinary urgency, urinary frequency, and nocturia. Patients with these symptoms, at the 5 clinical centers participating in the National Interstitial Cystitis Data Base (ICDB) Study, have been evaluated with history and physical exams, questionnaires, and urodynamic studies.
METHODS: Of the 388 female subjects entered in the study as of December 31, 1995, 150 women have undergone cystoscopy with hydrodistension. The data from the endoscopic procedures and the urodynamic studies were analyzed. The associations among cystoscopic and urodynamic findings were reviewed.
RESULTS: Patient demographics of this subgroup show a predominance of Caucasians 139/150 (92.7%), with the average age being 43 (+/-13.2) years. Of the total, 17 patients (11.3%) had a Hunner's patch (HP). The prevalence by center varied from a low of 2/38 (5.3%) to a high of 3/9 (33.3%). Bloody effluent following hydrodistension was present in 113/150 (75.3%). Glomerulations appeared in varying degrees (mild, moderate, severe) in 91.3% of the 150 patients. There was a strong inverse relationship (P < 0.001) between bladder capacity under anesthesia and the presence of a HP (mean of 845 cc with HP absent versus a mean of 531 cc when present). The incidence of HP varied from 67.6% among women with a bladder capacity at hydrodistension of < 400 cc to 3.8% for those with a bladder capacity of at least 800 cc. The presence and increasing severity of glomerulations was positively associated (P < 0.003) with the presence of HP, ranging from 0/13 (0%) when glomerulations were not present to 6/31 (19.4%) when glomerulations were graded as severe. Of the patients with HP, 17/17 (100%) had glomerulations after hydrodistension. HP is more closely associated with the moderate to severe range of glomerulations (P < 0.01). Nearly half of the patients with HP or 8/17 (47.1%) had "moderate" glomerulations, while 6/17 (35.3%) had "severe" glomerulations. The volume at first sensation to void on urodynamics (mean 87 cc without HP versus 34.7 cc with HP) was highly inversely associated (P = 0.002) with the presence of HP, but not with any of the other cystoscopic findings. Of patients with HP, 94% had a volume at first sensation to void of < or = 50 cc where only 36% of patients without HP had a volume at first sensation to void of < or = 50 cc. The volume at maximum capacity on urodynamics was positively associated with the volume at hydrodistension (P < 0.001).
CONCLUSIONS: Overall, patients with HP had lower bladder capacities, lower volumes at first sensation to void, and more severe glomerulations. Thus, the presence of HP would imply a more severe case of interstitial cystitis. Logically, a higher bladder capacity on cystometrogram is associated with a higher volume at the time of hydrodistension, and bloody effluent is associated with more severe glomerulations.

Entities:  

Mesh:

Year:  1997        PMID: 9146007     DOI: 10.1016/s0090-4295(99)80337-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  11 in total

1.  Diagnosis of interstitial cystitis June 2007.

Authors:  Lesley K Carr; Jacques Corcos; J Curtis Nickel; Joel Teichman
Journal:  Can Urol Assoc J       Date:  2009-02       Impact factor: 1.862

2.  Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail.

Authors:  Man-Jung Hung; Yi-Ting Chen; Pao-Sheng Shen; Shih-Tien Hsu; Gin-Den Chen; Esther Shih-Chu Ho
Journal:  Int Urogynecol J       Date:  2012-03-17       Impact factor: 2.894

3.  CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome.

Authors:  Ashley Cox; Nicole Golda; Genevieve Nadeau; J Curtis Nickel; Lesley Carr; Jacques Corcos; Joel Teichman
Journal:  Can Urol Assoc J       Date:  2016-05-12       Impact factor: 1.862

4.  Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis.

Authors:  Adam Gafni-Kane; Sylvia M Botros; Hongyan Du; Robert I Sand; Peter K Sand
Journal:  Int Urogynecol J       Date:  2012-06-15       Impact factor: 2.894

Review 5.  Differential diagnosis of chronic pelvic pain in women: the urologist's approach.

Authors:  Sophie G Fletcher; Philippe E Zimmern
Journal:  Nat Rev Urol       Date:  2009-09-01       Impact factor: 14.432

Review 6.  The placebo and nocebo effects in functional urology.

Authors:  Hadi Mostafaei; Sandra Jilch; Greta Lisa Carlin; Keiichiro Mori; Fahad Quhal; Benjamin Pradere; Ekaterina Laukhtina; Victor M Schuettfort; Abdulmajeed Aydh; Reza Sari Motlagh; Claus G Roehrborn; Shahrokh F Shariat; Sakineh Hajebrahimi
Journal:  Nat Rev Urol       Date:  2021-12-23       Impact factor: 14.432

Review 7.  Interstitial cystitis: modern tools for an accurate diagnosis.

Authors:  Lisa Nipkow; Toby C Chai
Journal:  Curr Urol Rep       Date:  2003-10       Impact factor: 2.862

Review 8.  Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis.

Authors:  Jing-Liang Chen; Hann-Chorng Kuo
Journal:  Investig Clin Urol       Date:  2019-11-13

9.  Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis.

Authors:  Yuan-Hong Jiang; Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

10.  Differences in Urodynamic Parameters According to the Presence of a Hunner Lesion in Women With Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Sun Tae Ahn; Hyeong Guk Jeong; Tae Yong Park; Jong Wook Kim; Hong Seok Park; Du Geon Moon; Jeong Gu Lee; Mi Mi Oh
Journal:  Int Neurourol J       Date:  2018-01-31       Impact factor: 2.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.